BGI Pursues IPO

Genome sequencing company BGI is weighing an A­-share Chinese listing, FinanceAsia reports.

Although BGI's chief science officer Mao Mao has told Chinese media that the firm is planning to launch its IPO by the end of the year, a FinanceAsia source says that it's "very unlikely" that BGI would go public this year, given how slowly new Chinese IPOs are being approved.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.